Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma

Journal of Hepatology

Volumn 59, Issue 4, 2013, Pages 769-779

  Waidmann, Oliver ^a   Köberle, Verena ^a   Bettinger, Dominik ^b   Trojan, Jörg ^a   Zeuzem, Stefan ^a   Schultheiß, Michael ^b   Kronenberger, Bernd ^a   Piiper, Albrecht ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

CD163; Cell death; Hepatocellular carcinoma; M30; M65

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD163 ANTIGEN; PROTEIN M30; PROTEIN M65; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CASE CONTROL STUDY; CELL DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL PREDICTION; ULTRASOUND;

AFP; ALPHA-FETOPROTEIN; AREA UNDER THE RECEIVER OPERATING CURVE; AUROC; BARCELONA CLINIC LIVER CANCER; BCLC; C-REACTIVE PROTEIN; CANCER OF THE LIVER ITALIAN PROGRAM; CD163; CELL DEATH; CK; CLIP; CRP; CYTOKERATIN; ELISA; ENZYME-LINKED IMMUNOSORBENT ASSAY; HCC; HEPATOCELLULAR CARCINOMA; LASER INTERSTITIAL THERMAL THERAPY; LITT; M30; M65; MELD; MODEL OF END STAGE LIVER DISEASE; NASH; NON-ALCOHOLIC STEATOHEPATITIS; OS; OVERALL SURVIVAL; RADIOFREQUENCY ABLATION; RECEIVER OPERATING CURVE; RFA; ROC; SCD163; SOLUBLE CD163; TACE; TRANSARTERIAL CHEMOEMBOLISATION;

AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL DEATH; COHORT STUDIES; FEMALE; HUMANS; KERATIN-18; LIVER CIRRHOSIS; LIVER NEOPLASMS; MACROPHAGE ACTIVATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL;

EID: 84884411717     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.06.008     Document Type: Article

References (43)

1. H.B. El-Serag Hepatocellular carcinoma N Engl J Med 365 2011 1118 1127
2. T.M. Welzel, B.I. Graubard, S. Zeuzem, H.B. El-Serag, J.A. Davila, and K.A. McGlynn Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database Hepatology 54 2011 463 471
3. V. Mazzaferro, E. Regalia, R. Doci, S. Andreola, A. Pulvirenti, and F. Bozzetti Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 1996 693 699 (Pubitemid 26079803)
4. H.B. El-Serag, J.A. Marrero, L. Rudolph, and K.R. Reddy Diagnosis and treatment of hepatocellular carcinoma Gastroenterology 134 2008 1752 1763 (Pubitemid 351615415)
5. EASL-EORTC clinical practice guidelines Management of hepatocellular carcinoma J Hepatol 56 2012 908 943
6. A new prognostic system for hepatocellular carcinoma A retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators Hepatology 28 1998 751 755
7. J.M. Llovet, C. Brú, and J. Bruix Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 19 1999 329 338
8. L.P. Bechmann, C. Jochum, P. Kocabayoglu, J.P. Sowa, M. Kassalik, and R.K. Gieseler Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury J Hepatol 53 2010 639 647
9. D.G.N. Craig, P. Lee, E.A. Pryde, G.S. Masterton, P.C. Hayes, and K.J. Simpson Circulating apoptotic and necrotic cell death markers in patients with acute liver injury Liver Int 31 2011 1127 1136
10. B. Kronenberger, M. Wagner, E. Herrmann, U. Mihm, A. Piiper, and C. Sarrazin Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C J Viral Hepat 12 2005 307 314 (Pubitemid 40638039)
11. D. Joka, K. Wahl, S. Moeller, J. Schlue, B. Vaske, and M.J. Bahr Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis Hepatology 55 2012 455 464
12. H. Farnik, C.M. Lange, W.P. Hofmann, A. Berger, R. Allwinn, and M.W. Welker Nucleos(t)ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B J Clin Virol 52 2011 204 209
13. R.A. Roberts, P.E. Ganey, C. Ju, L.M. Kamendulis, I. Rusyn, and J.E. Klaunig Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis Toxicol Sci 96 2007 2 15 (Pubitemid 46323203)
14. A.M. Elsharkawy, and D.A. Mann Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis Hepatology 46 2007 590 597 (Pubitemid 47344795)
15. S.K. Moestrup, and H.J. Møller CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response Ann Med 36 2004 347 354 (Pubitemid 39233102)
16. L.K. Weaver, K.A. Hintz-Goldstein, P.A. Pioli, K. Wardwell, N. Qureshi, and S.N. Vogel Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163 J Leukoc Biol 80 2006 26 35 (Pubitemid 44835523)
17. H.J. Møller Soluble CD163 Scand J Clin Lab Invest 72 2012 1 13
18. A. Klein, M. Zhadkewich, J. Margolick, J. Winkelstein, and G. Bulkley Quantitative discrimination of hepatic reticuloendothelial clearance and phagocytic killing J Leukoc Biol 55 1994 248 252 (Pubitemid 24066350)
19. H.J. Møller, H. Grønbaek, F.V. Schiødt, P. Holland-Fischer, M. Schilsky, and S. Munoz Soluble CD163 from activated macrophages predicts mortality in acute liver failure J Hepatol 47 2007 671 676 (Pubitemid 47503425)
20. P. Holland-Fischer, H. Grønbæk, T.D. Sandahl, S.K. Moestrup, O. Riggio, and L. Ridola Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS Gut 60 2011 1389 1393
21. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark Reporting recommendations for tumor marker prognostic studies (REMARK) J Natl Cancer Inst 97 2005 1180 1184 (Pubitemid 41258223)
22. J.M. Llovet, A.M. Di Bisceglie, J. Bruix, B.S. Kramer, R. Lencioni, and A.X. Zhu Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
23. R.N. Pugh, I.M. Murray-Lyon, J.L. Dawson, M.C. Pietroni, and R. Williams Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 1973 646 649
24. P.S. Kamath, R.H. Wiesner, M. Malinchoc, W. Kremers, T.M. Therneau, and C.L. Kosberg A model to predict survival in patients with end-stage liver disease Hepatology 33 2001 464 470 (Pubitemid 32119037)
25. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
26. H. Grønbaek, T.D. Sandahl, C. Mortensen, H. Vilstrup, H.J. Møller, and S. Møller Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis Aliment Pharmacol Ther 36 2012 173 180
27. M. Peck-Radosavljevic Back to basics: staging and prognosis in HCC for medical oncologist J Hepatol 56 2012 488 489
28. J. Cervoni, T. Thévenot, D. Weil, E. Muel, O. Barbot, and F. Sheppard C-reactive protein predicts short-term mortality in patients with cirrhosis J Hepatol 56 2012 1299 1304
29. S. Nagaoka, T. Yoshida, J. Akiyoshi, J. Akiba, T. Torimura, and H. Adachi Serum C-reactive protein levels predict survival in hepatocellular carcinoma Liver Int 27 2007 1091 1097 (Pubitemid 47399443)
30. W. Sieghart, M. Pinter, F. Hucke, I. Graziadei, M. Schöniger-Hekele, and C. Müller A single determination of C-reactive protein at the time of diagnosis predicts long term outcome of patients with hepatocellular carcinoma Hepatology 57 2013 2224 2234
31. A. Greystoke, E. Dean, M.P. Saunders, J. Cummings, A. Hughes, and M. Ranson Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer Br J Cancer 107 2012 1518 1524
32. K. Oyama, S. Fushida, J. Kinoshita, K. Okamoto, I. Makino, and K. Nakamura Serum cytokeratin 18 as a biomarker for gastric cancer Clin Exp Med 2012 [Epub ahead of print]
33. B. Oven Ustaalioglu, A. Bilici, S. Ercan, A. Orcun, M. Seker, and A. Ozkan Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls Clin Transl Oncol 14 2012 356 361
34. E. Yaman, U. Coskun, B. Sancak, S. Buyukberber, B. Ozturk, and M. Benekli Serum M30 levels are associated with survival in advanced gastric carcinoma patients Int Immunopharmacol 10 2010 719 722
35. C. Dive, R.A. Smith, E. Garner, T. Ward, S.S. George-Smith, and F. Campbell Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer Br J Cancer 102 2010 577 582
36. C. Ausch, V. Buxhofer-Ausch, U. Olszewski, and G. Hamilton Circulating cytokeratin 18 fragments and activation of dormant tumor cells in bone marrow of cancer patients Exp Ther Med 1 2010 9 12
37. R. de Franchis, and Baveno V. Faculty Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension J Hepatol 53 2010 762 768
38. O. Waidmann, F. Brunner, E. Herrmann, S. Zeuzem, A. Piiper, and B. Kronenberger Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis J Hepatol 58 2013 956 961
39. R. de Vito, A. Alisi, A. Masotti, S. Ceccarelli, N. Panera, and A. Citti Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease Int J Mol Med 30 2012 49 56
40. I. Shabo, and J. Svanvik Expression of macrophage antigens by tumor cells Adv Exp Med Biol 714 2011 141 150
41. M.B. Maniecki, A. Etzerodt, B.P. Ulhøi, T. Steiniche, M. Borre, and L. Dyrskjøt Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells Int J Cancer 131 2012 2320 2331
42. H. Hasita, Y. Komohara, H. Okabe, T. Masuda, K. Ohnishi, and X.F. Lei Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma Cancer Sci 101 2010 1913 1919
43. H. Kurahara, H. Shinchi, Y. Mataki, K. Maemura, H. Noma, and F. Kubo Significance of M2-polarized tumor-associated macrophage in pancreatic cancer J Surg Res 167 2011 e211 e219